As of January 2022, the American Diabetes Association identified a total of 491 cases of FG associated with SGLT-2 inhibitors, of which 162 were caused by canagliflozin, 101 cases of dapagliflozin, and 223 cases of empagliflozin and found a statistically significant increase in the risk of FG hospitalization with SGLT2i treatment compared to the use of two or more non-SGLT2 inhibitors or insulin therapy alone (3). Here, INS is linked to diabetes mellitus.